Drug Trial Radar · NCT01912677
Oral Antihypertensive Regimens for Management of Hypertension in Pregnancy
Last checked: Nov 19, 2026Latest source record: Nov 8, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
894
Actual
Start
Apr 2015
Primary completion
Sep 2017
Study completion Dec 2017
Sponsor
- Lead sponsor
- Gynuity Health ProjectsAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Government Medical College, Nagpur; Daga Memorial Women's Hospital, Nagpur, India; University of British Columbia; Bill and Melinda Gates Foundation
- First posted
- Jul 31, 2013
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years, up to 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a pragmatic, open-label, randomised control trial of three oral anti-hypertensive regimens for women with severe hypertension in pregnancy. Women presenting with severe hypertension in pregnancy in two hospitals in Nagpur, India will be randomised to one of three oral regimens: nifedipine, labetalol or methyldopa. This trial will compare the efficacy, safety and side effects of these three oral regimens for management of hypertension in pregnant women. The investigators hypothesize that nifedipine treatment of severe hypertensive parturient women is more effective than treatment with labetalol or methyldopa in controlling high blood pressure within six hours.
Conditions
- Hypertension in Pregnancy
- Preeclampsia
Interventions
NifedipineDrug
LabetalolDrug
MethyldopaDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Successful outcomeTime frame: 6 hours
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Daga Women's Hospital
Nagpur, Maharashtra, India
Government Medical College
Nagpur, Maharashtra, India
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.